Latest Market News

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.

IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.

Terrain Minerals (ASX: TMX) delivered a strong June quarter update, confirming high-grade gold and silver mineralisation at its Smokebush flagship, progressing a maiden resource estimate at Lightning, and reporting broad rare earth and lithium anomalies at Lort River and Carlindie projects.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Lumos Diagnostics is accelerating the rollout of its rapid FebriDx test in the US, with a top 100 urgent care group deploying across 30+ sites and three tier 1 groups validating the test across 230+ locations.

Beacon Minerals has paid a fully franked cash dividend of $0.10 per share, totalling approximately $11.63 million, as part of a broader shareholder return that includes an upcoming in-specie share distribution of Forrestania Resources.

Canterbury Resources is pushing ahead with a large-scale drilling program at its Briggs Copper Project while integrating its newly acquired Monto Project, setting the stage for a Pre-Feasibility Study on a potential tier-one copper operation.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

Silver Mines has confirmed robust economics for its Bowdens Silver Project, boosting ore reserves to 93.5 million ounces and outlining a 26-year mine life with a $455 million capital cost estimate.

EV Resources has successfully commissioned the flotation circuit at its Tecomatlán plant, setting the stage for processing bulk ore and producing its first marketable antimony concentrate as it advances toward commercial production.

Control Bionics has closed its Share Purchase Plan, raising $256,500 and pushing total capital raised to $9.75 million, pending shareholder approval for the final tranche.